# A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

> **NCT04089449** · PHASE1 · COMPLETED · sponsor: **Prelude Therapeutics** · enrollment: 86 (actual)

## Conditions studied

- Advanced Solid Tumor
- Recurrent Glioma

## Interventions

- **DRUG:** PRT811

## Key facts

- **NCT ID:** NCT04089449
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-06
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-03-28
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089449, "A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04089449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*